Income Statement
QUINCE THERAPEUTICS, INC.
QNCX
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY |
|---|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - | - |
|
Operating Expenses
|
57.29 | 34.62 | 52.02 | 90.32 | 78.89 | 39.17 |
|
Research & Development
|
18.59 | 9.45 | 25.18 | 60.80 | 61.31 | 30.21 |
|
Selling, General & Administrative
|
17.58 | 17.70 | 26.01 | 29.52 | 17.59 | 8.95 |
|
Other Operating Expenses
|
- | - | - | - | - | - |
|
Operating Income
|
-57.29 | -34.62 | -52.02 | -90.32 | -78.89 | -39.17 |
|
Non-Operating Income
|
- | - | - | - | - | - |
|
Interest Income
|
2.93 | 3.48 | 1.07 | 0.62 | 2.04 | - |
|
Interest Expense
|
- | - | - | - | - | - |
|
Other Non-Op Income / Expense
|
-0.68 | -0.10 | -1.00 | -0.25 | - | - |
|
Income Before Tax
|
-56.74 | -31.58 | -51.94 | -89.95 | - | - |
|
Income Tax Expense
|
0.09 | - | -0.30 | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - | - |
|
Net Income
|
-56.83 | -31.39 | -51.66 | -89.95 | -76.85 | -36.98 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY |
|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - |
|
EBITDA
|
-57.10 | -34.30 | -51.81 | -89.97 | -78.56 | -38.98 |
|
Earnings Per Share (Basic)
|
-1.31 | -0.84 | -1.54 | - | - | - |
|
Diluted EPS
|
-1.31 | -0.84 | -1.54 | - | - | - |
|
Weighted Average Shares
|
43.26 | 37.24 | 33.50 | - | - | - |
|
Diluted Weighted Avg Shares
|
43.26 | 37.24 | 33.50 | - | - | - |
|
Comprehensive Income
|
-59.91 | -28.05 | -51.87 | -90.34 | -76.60 | -36.87 |